SCHEDULE: Caligan Partners Reports 5% Stake in LB Pharmaceuticals

Caligan Partners LP and David Johnson have disclosed a beneficial ownership of 5.0% in LB Pharmaceuticals Inc., holding 1,438,070 shares.

Summary

• Caligan Partners LP, an investment manager, and David Johnson, its Managing Partner, have jointly filed a Schedule 13G.
• They collectively beneficially own 1,438,070 shares of LB Pharmaceuticals Inc. common stock.
• This ownership stake represents 5.0% of the company's outstanding common stock.
• The filing is based on the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which reported 28,674,827 shares outstanding as of March 23, 2026.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral score as the filing is a routine disclosure of beneficial ownership and does not contain performance data or strategic announcements that would indicate a positive or negative sentiment.

Positives

• Caligan Partners LP and David Johnson have taken a significant stake, indicating confidence in LB Pharmaceuticals Inc.
• The 5.0% ownership is a notable position, potentially signaling strategic interest or a belief in future growth.

Risks

• The filing does not explicitly mention any risks, as it is a Schedule 13G reporting beneficial ownership.
• Potential future risks could arise if the reporting persons' investment strategy changes or if market conditions for LB Pharmaceuticals Inc. deteriorate.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It is a disclosure of current beneficial ownership.

Management Comments

• Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.

Industry Context

StockSavvy.ai notes that a Schedule 13G filing by an investment manager like Caligan Partners LP, indicating a 5% stake, is a common disclosure for institutional investors who have acquired a significant position in a publicly traded company. This often signals a belief in the company's value or potential, but without further context from the company's own disclosures, it's difficult to ascertain the specific strategic intent beyond passive investment.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest in LB Pharmaceuticals Inc., potentially influencing market perception and share price.
• Management: The company's management will be aware of Caligan Partners LP's significant stake, which could influence future strategic discussions or board composition if the stake grows.
• Regulators: The filing ensures compliance with SEC disclosure requirements for significant shareholders.

Next Steps

• Caligan Partners LP and David Johnson will continue to hold their shares in LB Pharmaceuticals Inc.
• Further filings may be required if their beneficial ownership changes significantly.

Key Dates

Keywords

LB Pharmaceuticals Inc, Schedule 13G, Caligan Partners LP, David Johnson, Beneficial Ownership, Investment Management, SEC Filing, Common Stock, 5% Stake